


# THE SENSOREADY® PEN:

A DEMONSTRATION KIT FOR HEALTHCARE PROVIDERS

## SENSOREADY® PEN (50MG)



HELPING YOU SHOW THEM THE WAY

**SANDOZ** A Novartis  
Division

GR2004241739

  
**Erelzi**<sup>™</sup>  
etanercept

May 2020

This kit provides you with a demonstration version of the Erelzi® SensoReady® pen. This has been designed to allow you to learn how to demonstrate the self-injection device to your patients. You can reset the device after each use to allow for multiple patient demonstrations.

The SensoReady® pen is a device that delivers Erelzi® (etanercept) subcutaneously. The device is available for a 50 mg injection.<sup>1</sup>

**This SensoReady® pen demonstration device does not contain the actual drug or a needle and is safe for patients to practice with.**

The demonstration device has an expiry date of 3 years. Please contact your local Sandoz Sales representative if the demonstration device stops functioning.

## BEFORE THE SENSOREADY® PEN DEMONSTRATION

Reassure the patient that this is a demonstration device. However, the aim of their time with you is to familiarise them with the device to ensure that their self-administration is simple and stress-free.

**Ensure that you run through the following safety checks to encourage good safety habits in the patient - these checks need to be followed when your patients inject their active Erelzi®:**

- **Check** that the pen is within the expiry date.<sup>1</sup>
- **Check** that the liquid is clear or slightly opalescent, colourless, or slightly yellowish. It may contain small white or almost transparent particles of protein.<sup>1</sup>
- **Check** that the safety seal is not broken.<sup>1</sup>

*If any of these checks fail, the patient should return their pen to the pharmacy.<sup>1</sup>*

Please refer to Summary of Product Characteristics (SmPC) before prescribing. Full prescribing information is available at: <https://www.ema.europa.eu/en>

### References

1. Erelzi® Package Leaflet: Information for the user Nov 2019. Date of preparation: April 2020. HQ/ETA/17-006

### Call for reporting

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Suspected Adverse Drug Reactions (side effects) and medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at <http://www.medicinesauthority.gov.mt/adrportal> and sent by post or email to:

**P:** Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Zammit Buildings, Malta Life Sciences Park, San Gwann, SGN 3000.

**E:** [postlicensing.medicinesauthority@gov.mt](mailto:postlicensing.medicinesauthority@gov.mt).

Healthcare Professionals may also report any adverse events associated with the use of **Erelzi®** to Novartis Pharma Services Inc., Representative Office, Malta, by phone on +356 21222872, online on [www.report.novartis.com](http://www.report.novartis.com) or by e-mail at [drug\\_safety.malta@novartis.com](mailto:drug_safety.malta@novartis.com).


Marketing Authorization Holder: Sandoz GmbH Biochemiestr. 10 A-6250 Kundl Austria

Local Distributor: V.J. Salomone Pharma Limited - Upper Cross Road, Marsa, MRS 1542, Malta


**For electronic copies of this Educational Material, please refer to the Malta Medicines Authority website - <http://www.medicinesauthority.gov.mt/rmm> - and download the required material with the latest date.**

GR2004241739


## HOW TO USE THE SENSOREADY® PEN DEMONSTRATION DEVICE




- This device has no needle but instead includes a white plastic part that allows the injection process to be demonstrated without piercing the skin
- *Highlight to the patient that they need to clean the injection site with an alcohol swab<sup>1</sup>*
- Twist off the cap in the direction of the arrows<sup>1</sup>




- Find a suitable injection site on the patient's body<sup>1</sup>
- *Highlight suitable injection sites to the patient<sup>1</sup>*
- Place the pen vertically (at a 90° angle)<sup>1</sup>



- Press the pen firmly against the patient's skin to begin the injection. Keep holding the pen firmly against their skin<sup>1</sup>
- During the injection, you should hear two clicks: the first click means that the injection has started, and the second click means that the injection has almost finished<sup>1</sup>
- *Explain the meaning of these clicks to the patient*



- Check that the green indicator fills the window and has stopped moving.<sup>1</sup> The pen can now be removed
- *Explain to the patient how to safely dispose of the SensoReady® Pen and emphasise that they should never reuse their device<sup>1</sup>*



- To reset the demo version in this box, simply replace the lid on the pen. It will be reset when you remove the lid.

May 2020